Publications

2019

Farber G, Parks MM, Guahmich NL, Zhang Y, Monette S, Blanchard SC, et al. ADAM10 controls the differentiation of the coronary arterial endothelium. Angiogenesis. 2019;22(2):237-250.
Cross T, Ransegnola B, Shin J-, Weaver A, Fauntleroy K, VanNieuwenhze MS, et al. Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens. Antimicrob Agents Chemother. 2019;63(9).
Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, et al. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia. 2019;33(3):696-709.
Navrazhina K, Hibler BP, Magro CM, Wildman HF. Beach Bummer: A Recurrent Pruritic Buttocks Eruption Following Travel. Am J Med. 2019;132(8):931-933.
Chen B-, Quinet A, Byrum AK, Jackson J, Berti M, Thangavel S, et al. XLF and H2AX function in series to promote replication fork stability. J Cell Biol. 2019;218(7):2113-2123.
Zadra G, Loda M. When fat goes down, prostate cancer is on the ropes. Mol Cell Oncol. 2019;6(3):1595308.
Toyoda Y, Franck P, Brownstone ND, Lieberman M, Magro CM, Otterburn DM. Apocrine adenocarcinoma in the setting of apocrine hidrocystoma of the leg. Dermatol Online J. 2019;25(6).
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10(1):2977.
Ware AD, Murdock T, Voltaggio L, Windon AL, Troncoso JC, Hruban RH, et al. The "Race" Toward Diversity, Inclusion, and Equity in Pathology: The Johns Hopkins Experience. Acad Pathol. 2019;6:2374289519873104.
Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700